期刊文献+

滤泡性淋巴瘤患者预后相关因素分析 被引量:1

Analysis of prognostic factors in patients with follicular lymphoma
下载PDF
导出
摘要 目的探讨滤泡性淋巴瘤患者预后的相关因素。方法回顾性分析59例滤泡性淋巴瘤患者的临床资料,结合随访资料,对FL预后影响因素进行单因素和多因素分析。结果单因素分析结果表明:患者的临床分期、Hb、结外病灶数目、B组症状有无、PS评分与预后密切相关,FLIPI不同评分各组预后差异有显著性;采用Cox回归模型进行多因素分析,结果显示:临床分期、PS得分、结外病变数、CD20单克隆抗体治疗是滤泡性淋巴瘤患者预后的影响因素。结论滤泡性淋巴瘤患者的预后与多种因素及治疗方法有关,合理调控相关因素及采用免疫联合化疗的方法治疗可以延长患者的生存。 Objective The purpose of this study is to investigate the prognostic factors of follicular lymphoma (FL) patients. Methods Retrospective analysis was used in 59 case of FL patients with clinical data. Combined with follow-up data, single factor analysis and COX regression analysis methods were applied to study the prognostic factors of FL patients.Results The single factor analysis showed that patient's clinic stage, Hb,number of extranodal lesions,B symptoms,and PS score have significant effect on the five year survival rate of FL patients. COX regression analysis showed that patient's clinic stage,PS score, number of extranodal lesions,and CD20 monoclonal antibody therapy were the prognostic factors of FL patients. Conclusion The prognosis of FL patients is correlated with a variety of factors and treatment methods. Reasonable regulation of the correlated factors and the use of immune--related treatment methods combined with chemotherapy can prolong survival.
出处 《济宁医学院学报》 2011年第6期407-409,共3页 Journal of Jining Medical University
关键词 淋巴瘤 滤泡型 预后 临床研究 Lymphoma Follicular Prognosis Clinical research
  • 相关文献

参考文献10

  • 1Finn WG. Kroft SH New classifications for non-Hodgkin's lymphoma[J]. Cancer Treat Res, 1999,99: 1-26.
  • 2沈杨,李军民.滤泡型淋巴瘤治疗进展[J].中国实用内科杂志,2007,27(24):1891-1893. 被引量:1
  • 3常乃柏(综述).滤泡性淋巴瘤的临床特点、预后及治疗[J].白血病.淋巴瘤,2009,18(8):496-499. 被引量:4
  • 4邹霜梅,应建明,薛丽燕,郑闪,刘秀云,温芃,吕宁.MUM1/IRF4在滤泡性淋巴瘤中的表达及其临床病理意义[J].白血病.淋巴瘤,2011,20(6):353-356. 被引量:7
  • 5Sehulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systemic review and meta-analysis[J]. J Natl Cancer Inst,2007,99:706-714.
  • 6Canioni D, Salles G, Mounier N, et al. High numbers of tumor associated macrophages have an adverse prognostic value that can be circumvented by rituximad in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trail[J]. J Clin Oncol, 2008,26: 440-446.
  • 7Hirt C, Schuler F, Kiefer T, et al. Rapid and sustained dearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t (14;18)PCR monitoring in advanced stage follicular lymphoma patients[J].Br J Haematol, 2008,141: 631-640.
  • 8Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without ritoximab during induction: results of a propective randomized phase Ⅲ intergroup trial[J]. Blood, 2006, 108 : 3295 3301.
  • 9Mclanghlin P, Hagemeister F B,Grillo-Lopez A J, et al. Rit uximab in indolent lymphoma: the single-agent pivotal trial [J]. Semin Oncol,1999,26(5 Suppl 14):79-87.
  • 10Ghielmini M, Rufibach K, Salles G, et al. Single agent ritux imab in patients with follicular or mantle cell lymphoma:clin ical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system:a study of the Swiss Group for Clinical Canc- er Research(SAKK) [J]. Ann Oncol, 2005, 16 (10): 1675- 1682.

二级参考文献61

  • 1Sato Y, Ichimura T, Takata K, et al. Duodenal follicular lymphomas share common charateristics with mucosa-associated lymphoid tissue lymphomas. J Clin Pathol, 2008, 61: 377-381.
  • 2Kim BK, Surti U, Pandya A, et al. Clinicophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphoma. Am J Surg Pathol, 2005, 29: 69-82.
  • 3Cong P, Raffeld M, Teruya-Feldstein J, et al. In situ localization follicular lymphoma: description and analysis by laser capture microdissection. Blood, 2002, 99: 3376-3382.
  • 4Roulland S, Navarro J, Grenot P, et al. Follicular lymphoma-like B cells in healthy individuals:a novel intermediate step in early lymphomagenesis. J Exp Med, 2006, 203: 2425-2431.
  • 5Solal-Celigni P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood, 2004, 104:1258-1265.
  • 6Farinha P, Masoudi H, Skinnider BP, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 2005, 106: 2169-2174.
  • 7Dave SS, Wright G, Tan B, et al. Predictor of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Eng J Med, 2004, 351: 2159-2169.
  • 8Byers R, Sakhinia E, Joseph P, et al. Clinical quantitation of immune signiture in follicular lymphoma by RT-PCR-based gene expression profiling. Blood, 2008, 111: 4764-4770.
  • 9Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infihrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 2006, 108: 2957-2960.
  • 10Taskinen M, Karjalainen-Lindsburg M, Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood,' 2008, 111: 4664-4667.

共引文献9

同被引文献9

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部